Janus激酶抑制剂在皮肤病治疗中的应用前景  

Prospects of Janus kinase inhibitors in the treatment of skin diseases

作　　者：李明 周俐宏 李邻峰[1] Li Ming;Zhou Lihong;Li Linfeng(Department of Dermatology,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China)

机构地区：[1]首都医科大学附属北京友谊医院皮肤科,100050

出　　处：《中华皮肤科杂志》2020年第10期845-848,共4页Chinese Journal of Dermatology

摘　　要：Janus激酶(JAK)和信号转导和转录激活因子(STAT)所构成的JAK-STAT信号通路是一条重要的细胞内信号通路,参与许多炎症性疾病的发病。JAK抑制剂阻断该通路已经成为治疗某些疾病的有效方法,例如类风湿关节炎、溃疡性结肠炎。然而,目前JAK抑制剂尚未被批准应用于皮肤病治疗。本文就JAK抑制剂在皮肤疾病中的应用前景进行综述。The JAK-STAT signaling pathway,composed of Janus kinase(JAK)and signal transducer and activator of transcription(STAT),is an important intracellular signaling pathway.It is involved in the occurrence of many inflammatory diseases.Blocking this pathway by JAK inhibitors has become an effective approach to the treatment of some diseases,such as rheumatoid arthritis and ulcerative colitis.However,JAK inhibitors have not been approved for the treatment of skin diseases at present.This review summarizes application prospects of JAK inhibitors in the treatment of skin diseases.

关 键 词：Janus激酶类 蛋白激酶抑制剂 信号传导 皮肤疾病 炎症性皮肤病 治疗结果 药物毒性 

分 类 号：R751.05[医药卫生—皮肤病学与性病学]